TITLE

Between the Lines

AUTHOR(S)
Park, Alice
PUB. DATE
June 2000
SOURCE
Time International (South Pacific Edition);6/5/2000, Issue 22, p102
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses the treatments for cancer that are being experimented with as of June 5, 2000. Treatments discussed at the American Society of Clinical Oncology's annual meeting; Description of smart drugs, which are targeted on the proteins that nurture tumor cells; Details of the three phases that a drug must pass before it is approved by the United States Food and Drug Administration (FDA). INSETS: FANTASTIC VOYAGE;COFFEE SHAKE-UP;BEAT YOUR CHEST;LIBIDO LETDOWN, by Janice M. Horowitz
ACCESSION #
3175350

 

Related Articles

  • Amgen's Phase II Antibody Strong in Pancreatic Cancer. Osborne, Randy // BioWorld Today;6/7/2010, Vol. 21 Issue 108, p1 

    The article reports on the results of a Phase II clinical trial of Prolia presented by Amgen Inc. at the 2010 meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The trial involved 122 patients with pancreatic cancer, forty of which were given AMG 479, a monoclonal...

  • New targets, new drugs highlight oncology meeting. McCann, Jean // Drug Topics;6/4/2001, Vol. 145 Issue 11, p27 

    Highlights the 2001 meeting of the American Society of Clinical Oncology. Conclusion of the phase I clinical trial of EntreMed's angiostatin inhibitor endostatin; Treatment for cancers.

  • Tracking a cancer cure. Marcus, Mary Brophy // U.S. News & World Report;06/01/98, Vol. 124 Issue 21, p52 

    Summarizes new cancer studies presented at the May, 1998 meeting of the American Society of Clinical Oncology. Drugs called Camptosar, Taxol, and Herceptin; Use of selective estrogen receptor modulators, or SERMs; Prostate specific antigen (PSA) blood tests; Smoking and the development of...

  • ASCO to Congress: PDUFA Drug Shortage Provision Needs Teeth. Serebrov, Mari // BioWorld Today;6/5/2012, Vol. 23 Issue 108, p1 

    The article focuses on the highlights of a panel discussion at the 2012 meeting of the American Society of Clinical Oncology (ASCO). The panel urges the U.S. Congress to improve a Prescription DXrug User Fee Act (PDUFA) V provision that requires companies to notify the Food and Drug...

  • ASCO Presentations Reinforce Lymphoseek Clinical Development Approach and Regulatory Pathway.  // Biomedical Market Newsletter;6/9/2011, p200 

    The article focuses on the NEO3-09 clinical trial of Lymphoseek from medical products developer Neoprobe Corp. presented at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois. It says that Neoprobe is confident that the study design, execution, and regulatory input of...

  • Ligand to Advance Clinical Development of Captisol-enabled(r), Propylene Glycol- Free Melphalan for Multiple Myeloma.  // Biomedical Market Newsletter;6/30/2011, p433 

    The article reports on the decision of Ligand Pharmaceuticals Inc. to advance development of its Captisol-enabled melphalan program for multiple myeloma in San Diego, California. It notes the goal of the company to file a New Drug Application (NDA) with the U.S. Food and Drug Administration...

  • Feature Analysis: ASCO meeting 2009: current blockbusters advance standard care in new indications.  // PharmaWatch: Monthly Review;Jul2009, Vol. 8 Issue 7, p6 

    Information about the 45th annual meeting of the American Society of Clinical Oncology (ASCO), held in Orlando, Florida is presented. The focus of the conference was the personalization of cancer care and the proliferation of targeted therapies. The event also highlighted the synergistic...

  • Investigational Drug Shows Promise for CRPC. Schieszer, John // Renal & Urology News;Sep2010, Vol. 9 Issue 9, p24 

    The article offers information on the data showed at the annual meeting of the American Society of Clinical Oncology which reveals that the investigational drug Alpharadin may relieve pain and enhance the survival of patients with castration-resistant prostate cancer (CRPC).

  • With Immunotherapies, Patients May Live Though Tumors Grow. Breindl, Anette // BioWorld Insight;6/10/2013, Vol. 21 Issue 24, p1 

    The article focuses on various clinical trials presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois and discusses the use of the standard the Response Evaluation Criteria in Solid Tumors (RECIST) in randomized trials. It informs that results of...

Share

Read the Article

Other Topics